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Abstract
The aim of this paper is to use Markov modelling to
investigate survival for particular types of kidney patients
in relation to their exposure to anti-hypertensive treatment
drugs. In order to monitor kidney function an intuitive three
point assessment is proposed through the collection of blood
samples in relation to Chronic Kidney Disease for North-
ern Ireland patients. A five state Markov Model was de-
vised using specific transition probabilities for males and
females over all age groups. These transition probabilities
were then adjusted appropriately using relative risk scores
for the event death for different subgroups of patients. The
model was built using TreeAge software package in order to
explore the effects of anti-hypertensive drugs on patients.
1. Introduction
Worldwide, 10% of the adult population have some form
of kidney damage and every year millions die prematurely
from cardiovascular diseases linked to Chronic Kidney Dis-
ease (CKD) [1]. The number of patients receiving renal re-
placement therapy in the UK is rising rapidly and is unlikely
to reach steady state for another 25 years, costing 2% of the
total UK National Health Service (UK NHS) budget [2].
There is major concern that demand will soon outstrip re-
sources available in Nephrology care and dialysis centres,
of which there are only seven in Northern Ireland (NI). This
work focuses on modelling kidney function using estimated
Glomerular Filtration Rate (eGFR). GFR represents a per-
sons approximate percentage of kidney function however,
considering this is a difficult element to obtain from the
blood, one estimates this value using Leveys MDRD equa-
tion [3]:
eGFR = 186 ∗ (Creatinine/88.4)−1154 ∗ (Age)−0.203
∗ (0.742 if female) ∗ (1.210 if black) (1)
Previous work has shown that the recently corrected version
of the MDRD (known as the IDMS equation) is more accu-
rate and would be advised [4]. Internationally, there are five
known stages of CKD defined by eGFR, of which the latter
three are more severe [5]. These stages assist in construct-
ing states within the proposed Markov Model (MM) out-
lined in this paper. An intuitive categorisation method for
observing kidney function is used to calculate relative risk
of death for different subgroups of patients based on their
exposure to treatment drugs. A summary of how the transi-
tion probabilities were obtained for the MM is discussed as
well as features of the model when built using the software
package TreeAge [6]. The relative risk values are used to
adjust the current death probabilities for both the No CKD
state and CKD state. Analysis is performed which com-
pares survival curves for patients receiving treatment drugs
with those who did not receive the drugs.
2. Kidney Movement
A total of 2,892,340 blood samples from Northern Ire-
land were extracted during 1st Jan 01 - 31st Dec 02 from
regional laboratories. These were merged with an enriched
General Practice database producing a cohort of 75,434 pa-
tients, 20 years or older with a total of 307,663 test re-
sults. eGFR for each of these results was obtained using
the original MDRD equation as recommended (at the time)
by the National Institute for Health and Clinical Excellence
(NICE) [7]. In order to observe kidney movement within
the dataset a three point assessment was devised (repre-
sented by the points ABC on figure 1), where point B rep-
resents a patients minimum kidney function over the two
year period and points A and C identify the patients max-
imum kidney function before and after that minimum (if
one existed). This three point assessment, for each patient,
was categorised depending on whether the points lay above
or below a significant value of 60% kidney function [8],
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which resulted in 5 different possible groupings as shown
in figure 1. For example, group one represents patients
who throughout the two years maintained an eGFR above
60mls/min/1.73m2 (known as CKD stages 1 and 2) and thus
should arguably not pose demand on local kidney services.
In complete contrast, at the other end of the scale group 5
represents patients where all blood samples taken over the
two year period lay within CKD stages 3-5, that is below
60mls/min/1.73m2; the ‘danger zone’ as such.
Figure 1. Three point assessment and cate-
gorisation of patient kidney function
In addition the gradient slopes were calculated for each pa-
tient and those of particular interest, as directed by clinical
expert opinion, were patients who had a rapid progressive
slope >5mls/min/1.732 per year (represented by line AB
for each group in figure 1). Using this categorisation the
following descriptives were obtained from the data for 20+
year olds, using the original MDRD equation.
Group Patients Neph Deaths Rapids
1 56356 (74.7) 341 (29.2) 992 (28.5) 13600 (55.9)
2 2477 (3.3) 50 (4.3) 328 (9.4) 2363 (9.7)
3 2540 (3.4) 56 (4.8) 298 (8.6) 735 (3.0)
4 2812 (3.7) 73 (6.3) 495 (14.2) 2699 (11.1)
5 11249 (14.9) 647 (55.4) 1367 (39.3) 4919 (20.2)
Total 75434 1167 3480 24316
Notes: The values presented in brackets are the % within the column
‘Neph’ represents patient referrals to Nephrology
‘Rapids’ indicates patients with >5mls/min/yr progression
Table 1. Categorisation Descriptives
Early detection is a key factor in CKD, however its silent
symptoms make this a difficult, almost impossible task for
the majority affected. Ideally Nephrologists would like to
capture the rapid progressors, particularly those in groups
4 and 5, since these patients are in most danger of reach-
ing CKD stage 5, more commonly known as End Stage
Renal Failure (ESRF). The shaded cells in table 1 show
that Nephrologists in Northern Ireland had a potential 7,618
rapidly progressing patients (10.1% of the the total dataset)
in 2001/02 from groups 4 and 5 alone, of which only 720
were known to their care, possibly due to non-referrals
and/or lack of resources.
2.1. Relative Risk
Anti-hypertensive therapy (AHT) is used to reduce the
mortality and morbidity for patients with cardiovascular
complications. Considering hypertension is one of the main
risk factors for CKD, the use of Ace Inhibitors (ACEI)
and Antiotensin II Receptor Blocker (ARBs), two forms of
AHT, have been proven to slow the progression and devel-
opment of CKD [9]. This study examines the relative risk
(RR) for the event death when patients are exposed to the
treatment of ACEI/ARBs (AA) in comparison to those who
did not receive treatment (no AA). The RR was calculated
as shown
RR =
P(dying AA)
P(dying No AA)
(2)
=
Number died AA
Total AA
∗ Total No AA
Number died No AA
Adult kidney function starts to decay naturally beyond the
age of 40 (an approximate rule of thumb is 1ml/min/year).
Hence RR was calculated for different lower age boundaries
starting from 40+ year olds and also for those belonging to
groups 1-3 compared to those in groups 4-5 (figure 1), in
order to find the optimal subgroup of patients affected by
ACEI/ARBs in relation to death.
Age Relative Risk with 95% Confidence Limits
Criteria All Groups Groups 1-3 Groups 4-5
40+ 0.862 0.639 0.742
[0.791,0.939] [0.547,0.746] [0.670,0.821]
50+ 0.777 0.571 0.733
[0.713,0.847] [0.488,0.668] [0.661,0.812]
60+ 0.734 0.537 0.742
[0.672,0.801] [0.456,0.632] [0.669,0.823]
70+ 0.742 0.596 0.748
[0.676,0.814] [0.498,0.712] [0.670,0.835]
Notes: ‘Groups’ are outlined in figure 1
Table 2. Relative Risk Calculated for Different
Age Boundaries and Kidney Flow Groups
A RR<1 indicates that the event is less likely to occur in the
treatment group whereas a RR>1 suggests event is more
likely to occur in the treatment group. In this case, it can
be seen from the shaded cells in table 2 that the least risk
of death occurred for subjects who were 60 years of age
and above receiving the treatment drugs ACEI/ARBs. Us-
ing this subgroup of patients the RR was calculated again
for those who were rapidly declining (>5mls/min/year),
since these patients are in most danger and of extreme in-
terest to Nephrologists. This resulted in a RR of 0.515
([0.427,0.622] lower and upper 95% confidence intervals)
for patients in groups 1-3 and 0.728 ([0.654,0.812]) for
groups 4-5. In order to investigate this further, the following
5 state Markov model was utilised.
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3. The 5 State Markov Model for CKD
Internationally recognised CKD stages, as previously
discussed, help define states within the MM whereby stages
1 and 2 represent No CKD (>60% kidney function) and
stages 3-5 represent the CKD state (<60% kidney function)
in addition to the absorbing state Death. The typical length
of stay for patients highlighted that infact a 5 state MM was
necessary in order to capture the two-term mixed exponen-
tial flow of patients. This lead to the design of the 5 state
MM as shown in figure 2. It is important to note at this
point that the new corrected version of the MDRD equation
known as the IDMS was implemented for 18 year olds and
beyond as recommended by recent guidelines [7] leading to
a new larger dataset consisting of 77,615 patients with a to-
tal of 312,120 blood sample results [4].
Figure 2. The Five State Markov Model for
CKD
This model can be represented by a system of equations,
however for the purposes of this paper only a selection of
the system is shown. For example the probability that a
patient stays in No CKD state for at least x days is of the
general form
A1e
−β1(x−1) +A2e−β2(x−1) (3)
where
e−β1 = 1− r12 − r13 − r15 (4)
e−β2 = 1− r25 (5)
A1 =
r25 − r13 − r15
r25 − r12 − r13 − r15 = 1− k1 (6)
A2 =
−r12
r25 − r12 − r13 − r15 = k1 (7)
That is, β1 and β2 are the rates being estimated, rij repre-
sents the transition probability from state i to j and k1 is a
constant. By symmetry one can also calculate the probabil-
ity for the CKD state. Furthermore, it is possible to obtain
the number of patients in any state at time t, as an example
the Death state can be represented as follows:
dD(t)
dt
= NS(t)r15 +NL(t)r25 + CS(t)r35 + CL(t)r45
(8)
where NS and CS represent the No CKD and CKD short
stay states and NL and CL represent the No CKD and CKD
long stay states.
3.1. Model Assumptions and Methods
Transitions in this model between states (represented by
the arrows in figure 2) occur on a one day cycle length. Of-
ten Markov modelling is used to follow patient movement
in a health care setting, for example Taylor et al. [10] fo-
cused on geriatric patient movement within a hospital and
its community. However, the states outlined in this MM
are not actual physical places, instead they are a measure
of patient kidney function, given eGFR via blood sampling.
Considering the average patient does not require daily or
even weekly blood samples (unless perhaps hospitalised in
departments such as ICU or a dialysis unit etc), it is there-
fore necessary to assume that a particular patients kidney
function remains in the same state (i.e. condition) between
blood samples. Furthermore, it is assumed that whichever
state a patient initially enters the study, throughout the two
year period, then that is where the patients kidney function
would have been on the start date 1st Jan 2001, and vice-
versa for when a patient is leaving the study. A unique code
was written in MATLAB [11] to calculate the length of stay
before transition to another state for each patient as well as
the total number of patients in each state at any given time
t, where t ranges from 1 to 730 days.
The flow of patients leaving the No CKD or CKD states
was obtained by using Kaplan Meier in the software pack-
age SAS [12] to construct survivor distribution function es-
timates which were then fitted to the two-term mixed expo-
nential equations, an example of which are shown in equa-
tions 3-7. In addition, the number of patients in the death
state were fitted to equation 8 using ordinary differential
equations numerically in MATLAB via least squares min-
imisation. The optimal fits were found using a Nelder-Mead
method compiled in the fminsearch function in MATLAB.
Simulations were carried out in order to validate the result-
ing model for age and gender subcategories. The model was
further refined using Northern Ireland Statistics Research
Agency (NISRA) 2001 death rates [13] as a selection crite-
ria.
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Figure 3. The 5 State Markov Model Built in TreeAge
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4. TreeAge
TreeAge is a software package designed to facilitate
users in building various types of decision trees. In this
case, figure 3 displays the resulting MM built in TreeAge
using the structure previously illustrated in figure 2 as its
basis. The MM is reflected to make a mirror-image of the
model to allow for comparison of strategies. The aim of this
paper is to use Markov modelling to investigate survival for
particular types of kidney patients in relation to their expo-
sure to treatment, namely ACEI/ARBs. This stratification
can be seen in the branches labelled ‘No AA’ and ‘AA’. Be-
yond these branches a Markov node is in place consisting of
the 5 established states. A ‘chance’ node is attached to each
state followed by the path (branches) a patient may travel.
Below these branches the transition probabilities are stored
(in this case in the form of tables since the model is age and
gender dependent as discussed below). These branches also
have a ‘terminal’ node placed at the end represented by a
triangle; this indicates the last event in each path during a
cycle. At this point a patient is redirected to a state for the
next cycle length provided the model has not terminated (in
this case the model is set to run for 40 years, that is 14,600
cycle lengths).
It is important to note that the patients who die from the
No CKD state are patients who belong to groups 1-3 (see
figure 1) and must move to the death state using transition
probabilities r15 or r25. Alternatively, patients in groups
4-5 die from the CKD state and journey via transition prob-
abilities r35 or r45. An adjustment must be made to these
death probabilities r15, r25, r35 and r45 (see figure 2), us-
ing the previously calculated relative risk values (0.515 for
RR groups 1-3 and 0.728 for RR groups 4-5). Consider as
an example r15, firstly for patients who did not receive the
drug
New r15− =
Original r15
(RR group 1−3 ∗ ( Total AATotal Pats + Total No AATotal Pats ))
(9)
and then for patients who did receive the drug
New r15+ = RR group1-3 ∗ (New r15−) (10)
Similar calculations were performed for the three remaining
death probabilities r25, r35 and r45 at each age level and for
both genders.
4.1. Features and Limitations
Transition probabilities were recorded for every age
group 18-40, 40-50, 50-60, 70-80 and 80+ year olds. How-
ever since the optimal effects were found for 60+ year olds,
this means that the initial age for each subject in the tree
is defined as 21,900 (since the cycle length is recorded in
days) which can be observed at the start node in figure 3.
This feature allowed the model to track patients over time
and adjust their transitions accordingly by selecting the ap-
propriate row in the tables used (namely NoAA or AA).
A special feature is built into the model regarding gender,
whereby it is defined and randomly assigned at the start
node according to the ratio of females:males above 60 years
of age in the dataset. This is generated using the statement
gender=if(rand<=0.581;1;2) where 1 represents females
and 2 the males. Therefore branches of the tree are able
to select the appropriate column in a table dependent on
gender. It is essential in TreeAge to indicate what state(s)
subjects should enter the model by indicating a proportion
ranging from 0 to 1. This MM assumes that all patients ini-
tially enter via No CKD short or CKD short states. To cal-
culate the proportions accurately, the first blood sample for
all 60-70 year old patients in the dataset was recorded and
grouped depending if the eGFR was greater than 60mls/min
(No CKD state) or below that value (CKD state) thus result-
ing in proportions 0.794 and 0.206 respectively. All other
states were rewarded a 0 to indicate that subjects should not
enter the model via this route, as can be seen beneath the
states in figure 3.
One limitation of the five state MM is that the short stay
states lose their patients throughout the 2 year study period.
Considering the model in TreeAge spans 40 years (that
is the model has been set to terminate after 14,600 cycle
lengths), this meant that after a period of time patients
would move to No CKD long, leaving them no route to
enter the CKD state. In order to allow the model to function
realistically in TreeAge over long time periods a logic
branch was added to the tree using a function known as
‘modulo’. This loops the patients in the No CKD long
state back into the No CKD short state, on two yearly
intervals, hence reassesses their kidney function and allows
for transition to CKD state, if necessary, which clinically
resembles real life in that patients are often reassessed via
a visit to their local GP.
4.2. Survival
At each state an incremental reward was added to tally
the average life years gained for the no treatment MM ver-
sus the treatment MM. A state reward is a specified value
that is assigned to individuals when they spend one cycle
in a particular state. For this model, a variable was defined
at the start node as ‘ALE’ which equalled 1/365 consider-
ing cycle length is one day. Running the analysis on both
strategies and plotting the outcome shows the difference in
survival (see figure 4). Graphically, patients 60 years of age
and above receiving ACEI/ARBs who are rapidly declin-
ing have significantly higher survival (solid line) than those
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who do not receive the treatment (dashed line). The signifi-
cance of this result was strengthened by adjusting transition
probabilities according to patients RR for groups 1-3 and
4-5 separately, over all age groups and gender; thus indicat-
ing that it is worthwhile to categorise patients in this way in
order to maximise knowledge on the effects of these drugs.
In addition the incremental reward showed a difference of
3.9 life years gained for patients on ACEI/ARBs.
Figure 4. Survival of Treatment vs Control
Methods outlined above were repeated for other forms of
AHT drugs (not including ACEI/ARBs) however it is im-
portant to note that these drugs did not have a significant
effect on death when calculating the RR.
5. Conclusions and Further Work
A five state Markov model (MM) has been successfully
created for Northern Ireland Chronic Kidney Disease
(CKD) patients using a unique, robust technique for
calculating transition probabilities. This paper has shown
that the devised three point assessment and categorisation is
a worthwhile method of observing patient kidney function.
This assessment emphasises the amount of patients who
potentially required Nephrology care in 2001/2002 but
were not being captured by the system possibly due to
non-referral or lack of resources. Relative risk was used
for a practical example of how the MM could be exploited
in the software package TreeAge. It explored the effect
of treatment drug ACEI/ARBs and found that 60+ year
old patients who were rapidly declining (>5mls/min/year)
were less likely to die when prescribed with ACEI/ARBs
compared to those without the treatment. Further work will
involve attaching costs and utilities to the model in order to
evaluate the cost-effectiveness of administering these drugs
to more CKD patients, which also explores the suggestion
that primary care could have a high impact in caring for
CKD patients hence relieving the pressure of secondary
care facilities. The model will be expanded to seven states,
involving the separation of the current CKD state to include
an End Stage Renal Failure state for dialysis patients.
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